The Most Comprehensive Testing for Detecting Lyme Disease and TBRF Borrelia

Testing at IGeneX covers a wider spectrum of Lyme and TBRF Borrelia species.  We look for more and detect more with our in-house developed tests

Most labs use the CDC recommended tests for Western Blot or ImmunoBlot.

At IGeneX, we have developed a Lyme ImmunoBlot assay with specific recombinant proteins from several species of Borrelia burgdorferi sensu latu.   It detects most B. burgdorferi infection (Lyme) in the United States, Canada, Europe, and Australia.


IGeneX and the CDC recommended Lyme serology tests detect IgG and IgM antibodies in patient’s serum.

  • IgM antibody is the first antibody to appear in response to initial exposure or re-exposure to  burgdorferi.infection.
  • IgG antibody develops as a late response to the infection.

Lyme ImmunoBlot IgG or IgM are tests that detect specific antibodies from patient’s serum exposed to B. burgdorferi infection.  Lyme bacterial recombinant antigens are present on the ImmunoBlot strip. If Lyme specific antibodies are present in patient’s serum, it will bind to Lyme bacterial recombinant antigen present on the ImmunoBlot strip.  The bound antibody to specific protein bands on the ImmunoBlot strip will be detected with Alkaline Phosphatase(AP)conjugated goat anti-human antibody. Unbound antibody will be washed and a chromogenic substrate will detect the bound specific antibody. A dark purple colored precipitate will develop on antigen-antibody complex(band-kDa). Bands will be visualized and scored following IGeneX and CDC criteria. The CDC criteria for detecting specific protein (band-kDa) combination is very stringent whereas IGeneX criteria detects more specific antibodies. This is based on years of clinical experience and extensive validation of well characterized samples.


IGeneX result criteria produce a higher sensitivity for detecting Lyme exposure.

With IGeneX, combining the result criteria of reporting more significant protein bands give an increase sensitivity for detecting Lyme exposure. Now, using recombinant proteins to detect antibodies to more B. burgdorferi sensu lato species than the current Western blot prepared from two strains of B. burgdorferi produces a higher sensitivity and most comprehensive testing for Lyme disease antibodies in patient serum samples.


IGeneX TBRF ImmunoBlot has a high sensitivity for detecting TBRF exposure.

Most laboratories in US and Europe only offer the B. miyamotoi GlpQ protein serological assay whereas IGeneX, by including more recombinant antigens from several species of TBRF Borrelia on the ImmunoBlot provides improved sensitivity. Based on limited studies more than 50% of patients are missed if only B. miyamotoi GlpQ is used.